Pharma channel feed

Klick Health agency adds AI teams to ac­cel­er­ate phar­ma and health­care mar­ket­ing projects

Last year
AI
Marketing

FDA hands down ap­proval for Bris­tol My­er­s' lung can­cer drug from Turn­ing Point buy­out

Last year
FDA+

Heard at #Jef­feries23: Al­ny­lam, Bi­cy­cle, In­tel­lia, Nous­com, Rakuten Med­ical ex­ecs fore­cast 2024

Last year
People

No­vo Nordisk launch­es head-to-head tri­al with Eli Lil­ly as weight loss ri­val­ry heats up

Last year

Phar­mas and physi­cians val­ue med­ical af­fairs and MSLs, but have dif­fer­ent con­tent pri­or­i­ties, sur­vey says

Last year
Marketing

Ozem­pic short­ages have Eu­ro­pean coun­tries ex­plor­ing bans on use of pop­u­lar drug for weight loss

Last year
Manufacturing

CorMedix wins US ap­proval via rarely-used path­way for drug to re­duce blood­stream in­fec­tions

Last year
FDA+

Sanofi hands out com­mu­ni­ty health eq­ui­ty grants in on­go­ing ef­fort to build trust with mar­gin­al­ized groups

Last year
Marketing

A Mark Cuban copy? Cigna’s Ex­press Scripts to of­fer what it calls an­oth­er cost-plus pric­ing mod­el

Last year
Health Tech

Eli Lil­ly wins pre­lim­i­nary in­junc­tion in Moun­jaro case in drug­mak­er­s' on­go­ing bat­tle with com­pound­ing phar­ma­cies, well­ness spas

Last year
Marketing
Law

Can post-mar­ket ev­i­dence gen­er­a­tion be stream­lined? FDA-com­mis­sioned re­port pro­pos­es so­lu­tions

Last year
FDA+

FDA rais­es con­cerns over ef­fi­ca­cy of Mer­ck­'s po­ten­tial chron­ic cough drug ahead of ad­comm

Last year
FDA+

Pfiz­er to cut 500 jobs at Sand­wich, UK site

Last year
People

New NIH chief stress­es fo­cus on obe­si­ty, clin­i­cal tri­al chal­lenges

Last year
FDA+

No­var­tis adds to mul­ti­ple scle­ro­sis 'Love Sto­ry' cam­paign with more pa­tient per­spec­tives

Last year
Marketing

Mar­ket­ingRx roundup: Vi­a­tris de­buts new cam­paign in Times Square; As­traZeneca re­news nat­ur­al gas deal

Last year
Marketing

As­traZeneca's con­cur­rent Imfinzi-chemo-ra­di­a­tion com­bo in lung can­cer miss­es pri­ma­ry end­point in PhI­II tri­al

Last year
R&D

Japan con­sid­ers ad­just­ing clin­i­cal tri­al re­quire­ments to re­move the need for lo­cal stud­ies — re­port

Last year
FDA+

FDA ex­plains why it de­nied about 60% of non-on­col­o­gy break­through ther­a­py re­quests from 2017 to 2019

Last year
FDA+

Michi­gan to re­peal phar­ma in­dus­try's le­gal li­a­bil­i­ty shield from 1995

Last year
Law

GSK rais­es rare blood can­cer aware­ness with well-known ‘Queer Eye’ de­sign­er

Last year
Marketing

Af­ter show­ing We­govy cut car­dio­vas­cu­lar risk by 20%, re­sults de­tail im­pact on death and heart fail­ure

Last year
R&D

As­traZeneca pre­pares to live with the IRA, shift­ing fo­cus of ar­gu­ments to or­phan drug changes

Last year
Law

EMA com­mit­tee rec­om­mends ap­provals for Lil­ly's weight loss drug, Mi­rati's KRAS in­hibitor and more

Last year
FDA+
First page Previous page 89909192939495 Next page Last page
A service from the Financial Times